The new standard of price reduction for the products purchased with quantity will be reduced in this way

From the actions of Shanghai, it can be seen that whether it is the centralized purchase of drugs in 4 + 7 cities, the special centralized purchase of anti-cancer drugs in various provinces, or the volume purchase carried out by other forms of provincial alliance and hospital alliance, "price reduction" is a clear and visible trend What enterprises need to consider is more about how to reduce and how much At 9:30 a.m on January 17, the "4 + 7 urban volume procurement ventilation meeting for unsuccessful enterprises" was held in Shanghai Pharmaceutical centralized bidding procurement office Gong Bo, deputy director of the medical insurance Department of Shanghai human resources and Social Security Bureau, Zhu Shihui, deputy director of the Shanghai medicine centralized bidding and purchasing management office, and 4 + 7 non elected enterprise representatives attended the meeting In fact, the whole meeting mainly discusses two issues: first, how to reduce the price of 4 + 7 unsuccessful varieties? Second, how to link the result of winning the bid with the payment standard of medical insurance? 1 Failure to win the bid and price reduction are divided into three levels, and consistency evaluation is the key factor According to the pilot program for centralized purchase and use of drugs organized by the State Council issued by the general office of the State Council on January 17, volume purchase is to estimate the total purchase volume based on the purchase volume submitted by the public medical institutions in the pilot area and 60% - 70% of the total annual drug consumption of all the public medical institutions in the pilot area, and the remaining consumption All the public medical institutions can still purchase the provincial drug concentration Purchase other varieties with suitable price This leaves a certain living space for the varieties not winning the bid in 4 + 7 But the key question is, what is "price appropriate"? Shanghai gives the specific implementation plan One of the basic principles is to guide the original research products to reduce prices simultaneously, and to limit the prices of other products through consistency evaluation Shanghai Pharmaceutical Institute has set a red line, that is, the maximum price limit On this basis, enterprises are encouraged to further reduce prices or negotiate with medical institutions According to the information of the meeting, there are 24 product specifications involved in the unsuccessful enterprises except one product is exclusive According to the price difference between these products and the selected varieties, the proportion of price reduction shall be determined The price reduction ratio is divided into three grades, 10%, 20% and 30% respectively The basis of price reduction is the online price of corresponding varieties in Shanghai at the end of 2017 For some products that have been reduced in 2018, the actual purchase price in Shanghai in 2018 or the lowest bid price in 4 + 7 cities in 2017 should be reduced by at least 10% According to the above two conditions, the price reduction shall be subject to the lowest price, and the enterprise shall submit the price confirmation letter As for the products with different specifications from the bid winning products, the specifications shall be converted according to the price difference ratio The consistency evaluation will become an important factor to determine the fate of enterprises According to the content of the meeting, if there are more than three enterprises that have passed the consistency evaluation, the products that have not passed the consistency evaluation will be directly disqualified from networking; if there are less than three enterprises, the price of the products that have not passed the consistency evaluation cannot be higher than the selected products For the products that are not winning the bid, not the original research, belong to the consistency evaluation varieties, and are not the highest price among the products that are not winning the bid, the price red line set by the Pharmaceutical Institute is adopted, that is, the lowest purchase price of the product in Shanghai in 2017 and 2018 And this price can not be higher than the lowest price in 4 + 7 cities, and the price of the original research products after price reduction 2 The bid winning result is linked to the payment of medical insurance According to the pilot program of centralized purchase and use of drugs organized by the State Council issued by the general office of the State Council, the payment standard of medical insurance in the pilot cities should be coordinated with the purchase price The specific provisions are as follows: for the drugs purchased in a centralized way, the centralized purchase price shall be taken as the medical insurance payment standard within the scope of the medical insurance catalog In principle, for the original research drugs and reference preparations under the same general name and generic drugs passing the consistency evaluation, the medical insurance fund shall be settled according to the same payment standard If the price of drugs used by patients is higher than the payment standard, the part exceeding the payment standard shall be paid by the patients themselves If the price of drugs used by patients is quite different from the centralized purchase price of selected drugs, the payment standard can be adjusted gradually, adjusted in place within 2-3 years, and supporting policies and measures shall be formulated; if the price of drugs used by patients is lower than the payment standard, the actual price shall be paid On the basis of ensuring the quality and supply, guide the medical institutions and patients to form reasonable medication habits Shanghai's policy mainly embodies two principles, the first is still price reduction The second is to appropriately improve the patient's self payment standard In terms of increasing the proportion of self payment, Shanghai has set up two different types, namely, 10% increase in self payment and 20% increase in self payment For example, for essential drugs and class a medical insurance products, the proportion of out of pocket varieties that have not won the bid has increased by 10% Other products are up 20% Previously, Shanghai set a personal quota self payment standard for some targeted drugs that have been included in the medical insurance payment If this part of products fail to win the bid, the personal quota self payment standard will be directly increased by 20% However, if the promised price of the enterprise's price reduction reaches the bid winning price, the proportion of self payment will not be increased On the whole, Shanghai's policy on the unsuccessful products still reveals the trend of "price reduction" In fact, "price reduction" is a clear trend whether it is the centralized purchase of drugs in 4 + 7 cities, the special centralized purchase of anti-cancer drugs in various provinces, or the belt purchase carried out by other forms of provincial alliance and hospital alliance What enterprises need to consider is more about how to reduce and how much Before this battle, no one should be able to be alone.